Diana Vossen

Diana Vossen

Auto-generated profile, based on publicly available information

Diana Vossen

Ruhr University Bochum, Rheumazentrum Ruhrgebiet, Rheumatology, Bochum, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JKJohannes Knitza
Johannes Knitza
KTKoray TASCILAR
Koray TASCILAR
EMEva-Maria Messner
Eva-Maria Messner
MMMarco Meyer
Marco Meyer
DVDiana Vossen
Diana Vossen
MKMartin Krusche
Martin Krusche
Background: Chronic rheumatic diseases need long-term treatment and professional supervision. Mobile apps promise to improve the lives of patients and physicians. In routine practice, however, rheumatology apps are largely unknown and little is known about their quality and safety. Objective: The aim of this study was to provide an overview of mobile rheumatology apps currently available in German app stores, evaluate app quality using the Mobile Application Rating Scale (MARS), and compile brief, ready-to-use descriptions for patients and rheumatologists. Methods: The German App Store and Google Play store were systematically searched to identify German rheumatology mobile apps for patient and physician use. MARS was used to independently assess app quality by 8 physicians, 4 using Android and 4 using iOS smartphones. Apps were randomly assigned so that 4 apps were rated by all raters and the remaining apps were rated by two Android and two iOS users. Furthermore, brief app descriptions including app developers, app categories, and features were compiled to inform potential users and developers. Results: In total, 128 and 63 apps were identified in the German Google Play and App Store, respectively. After removing duplicates and only including apps that were available in both stores, 28 apps remained. Sixteen apps met the inclusion criteria, which were (1) German language, (2) availability in both app stores, (3) targeting patients or physicians as users, and (4) clearly including rheumatology or rheumatic diseases as subject matter. Exclusion criteria were (1) congress apps and (2) company apps with advertisements. Nine apps addressed patients and 7 apps addressed physicians. No clinical studies to support the effectiveness and safety of apps could be found. Pharmaceutical companies were the main developers of two apps. Rheuma Auszeit was the only app mainly developed by a patient organization. This app had the highest overall MARS score (4.19/5). Three out of 9 patient apps featured validated questionnaires. The median overall MARS score was 3.85/5, ranging from 2.81/5 to 4.19/5. One patient-targeted and one physician-targeted app had MARS scores >4/5. No significant rater gender or platform (iOS/Android) differences could be observed. The overall correlation between app store ratings and MARS scores was low and inconsistent between platforms. Conclusions: To our knowledge, this is the first study that systematically identified and evaluated mobile apps in rheumatology for patients and physicians available in German app stores. We found a lack of supporting clinical studies, use of validated questionnaires, and involvement of academic developers. Overall app quality was heterogeneous. To create high-quality apps, closer cooperation led by patients and physicians is vital.

20 July 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MKMartin Krusche
Martin Krusche
PKPhilipp Klemm
Philipp Klemm
MGManuel Grahammer
Manuel Grahammer
JMJohanna Mucke
Johanna Mucke
DVDiana Vossen
Diana Vossen
JKJohannes Knitza
Johannes Knitza
Background: The use of patient-reported outcomes (PROs) allows for patient-centered, measurable, and transparent care. Electronic PROs (ePROs) have many benefits and hold great potential to improve current usage of PROs, yet limited evidence exists regarding their acceptance, usage, and barriers among rheumatologists. Objective: This study aims to evaluate the current level of acceptance, usage, and barriers among German rheumatologists regarding the use of ePROs. The importance of different ePRO features for rheumatologists was investigated. Additionally, the most frequently used PROs for patients with rheumatoid arthritis (RA) were identified. Methods: Data were collected via an online survey consisting of 18 questions. The survey was completed by members of the Working Group Young Rheumatology of the German Society for Rheumatology (Arbeitsgemeinschaft Junge Rheumatologie der Deutschen Gesellschaft für Rheumatologie [DGRh]) at the 2019 annual DGRh conference. Only members currently working in clinical adult rheumatology were eligible to complete the survey. Results: A total of 119 rheumatologists completed the survey, of which 107 (89.9%) reported collecting PROs in routine practice and 28 (25.5%) already used ePROs. Additionally, 44% (43/97) were planning to switch to ePROs in the near future. The most commonly cited reason for not switching was the unawareness of suitable software solutions. Respondents were asked to rate the features of ePROs on a scale of 0 to 100 (0=unimportant, 100=important). The most important features were automatic score calculation and display (mean 77.50) and simple data transfer to medical reports (mean 76.90). When asked about PROs in RA, the respondents listed pain, morning stiffness, and patient global assessment as the most frequently used PROs. Conclusions: The potential of ePROs is widely seen and there is great interest in them. Despite this, only a minority of physicians use ePROs, and the main reason for not implementing them was cited as the unawareness of suitable software solutions. Developers, patients, and rheumatologists should work closely together to help realize the full potential of ePROs and ensure a seamless integration into clinical practice.

4 February 2020 in JMIR Preprints
Verified
Preprint
Open access
MKMartin Krusche
Martin Krusche
PKPhilipp Klemm
Philipp Klemm
MGManuel Grahammer
Manuel Grahammer
JMJohanna Mucke
Johanna Mucke
DVDiana Vossen
Diana Vossen
JKJohannes Knitza
Johannes Knitza
BACKGROUND The use of patient-reported outcomes (PROs) allows for patient-centered, measurable, and transparent care. Electronic PROs (ePROs) have many benefits and hold great potential to improve current usage of PROs, yet limited evidence exists regarding their acceptance, usage, and barriers among rheumatologists. OBJECTIVE This study aims to evaluate the current level of acceptance, usage, and barriers among German rheumatologists regarding the use of ePROs. The importance of different ePRO features for rheumatologists was investigated. Additionally, the most frequently used PROs for patients with rheumatoid arthritis (RA) were identified. METHODS Data were collected via an online survey consisting of 18 questions. The survey was completed by members of the Working Group Young Rheumatology of the German Society for Rheumatology (Arbeitsgemeinschaft Junge Rheumatologie der Deutschen Gesellschaft für Rheumatologie [DGRh]) at the 2019 annual DGRh conference. Only members currently working in clinical adult rheumatology were eligible to complete the survey. RESULTS A total of 119 rheumatologists completed the survey, of which 107 (89.9%) reported collecting PROs in routine practice and 28 (25.5%) already used ePROs. Additionally, 44% (43/97) were planning to switch to ePROs in the near future. The most commonly cited reason for not switching was the unawareness of suitable software solutions. Respondents were asked to rate the features of ePROs on a scale of 0 to 100 (0=unimportant, 100=important). The most important features were automatic score calculation and display (mean 77.50) and simple data transfer to medical reports (mean 76.90). When asked about PROs in RA, the respondents listed pain, morning stiffness, and patient global assessment as the most frequently used PROs. CONCLUSIONS The potential of ePROs is widely seen and there is great interest in them. Despite this, only a minority of physicians use ePROs, and the main reason for not implementing them was cited as the unawareness of suitable software solutions. Developers, patients, and rheumatologists should work closely together to help realize the full potential of ePROs and ensure a seamless integration into clinical practice.

10 June 2019 in JMIR Preprints
Verified
Preprint
Open access
JKJohannes Knitza
Johannes Knitza
KTKoray TASCILAR
Koray TASCILAR
EMEva-Maria Messner
Eva-Maria Messner
MMMarco Meyer
Marco Meyer
DVDiana Vossen
Diana Vossen
MKMartin Krusche
Martin Krusche
BACKGROUND Chronic rheumatic diseases need long-term treatment and professional supervision. Mobile apps promise to improve the lives of patients and physicians. In routine practice, however, rheumatology apps are largely unknown and little is known about their quality and safety. OBJECTIVE The aim of this study was to provide an overview of mobile rheumatology apps currently available in German app stores, evaluate app quality using the Mobile Application Rating Scale (MARS), and compile brief, ready-to-use descriptions for patients and rheumatologists. METHODS The German App Store and Google Play store were systematically searched to identify German rheumatology mobile apps for patient and physician use. MARS was used to independently assess app quality by 8 physicians, 4 using Android and 4 using iOS smartphones. Apps were randomly assigned so that 4 apps were rated by all raters and the remaining apps were rated by two Android and two iOS users. Furthermore, brief app descriptions including app developers, app categories, and features were compiled to inform potential users and developers. RESULTS In total, 128 and 63 apps were identified in the German Google Play and App Store, respectively. After removing duplicates and only including apps that were available in both stores, 28 apps remained. Sixteen apps met the inclusion criteria, which were (1) German language, (2) availability in both app stores, (3) targeting patients or physicians as users, and (4) clearly including rheumatology or rheumatic diseases as subject matter. Exclusion criteria were (1) congress apps and (2) company apps with advertisements. Nine apps addressed patients and 7 apps addressed physicians. No clinical studies to support the effectiveness and safety of apps could be found. Pharmaceutical companies were the main developers of two apps. Rheuma Auszeit was the only app mainly developed by a patient organization. This app had the highest overall MARS score (4.19/5). Three out of 9 patient apps featured validated questionnaires. The median overall MARS score was 3.85/5, ranging from 2.81/5 to 4.19/5. One patient-targeted and one physician-targeted app had MARS scores >4/5. No significant rater gender or platform (iOS/Android) differences could be observed. The overall correlation between app store ratings and MARS scores was low and inconsistent between platforms. CONCLUSIONS To our knowledge, this is the first study that systematically identified and evaluated mobile apps in rheumatology for patients and physicians available in German app stores. We found a lack of supporting clinical studies, use of validated questionnaires, and involvement of academic developers. Overall app quality was heterogeneous. To create high-quality apps, closer cooperation led by patients and physicians is vital.

10 September 2026 in Rheumatology International
Verified
Journal Article
Open access
PDF file
DVDiana Vossen
Diana Vossen
XBXenofon Baraliakos
Xenofon Baraliakos
MPMaria Polyzou
Maria Polyzou
Specialized pregnancy counselling improves maternal and infant outcomes in women with inflammatory rheumatic and musculoskeletal diseases (iRMDs). As such services are not universally available, large language models (LLMs) may increasingly serve as an accessible source of information for patients seeking guidance on family planning, pregnancy, and lactation. This highlights the need to evaluate this software in terms of their adequacy, accuracy and overall reliability. The aim of the analysis is to evaluate the possibility of using LLMs as reliable sources of information regarding female patients suffering from iRMD and going through the period of pregnancy. 54 questions were formulated, which concern the impact and general relationship between pregnancy and rheumatic diseases. The questions were given to four LLMs, ChatGPT, DeepSeek, Gemini and Grok, and the corresponding answers were obtained. The responses were rated across three clinical domains on a 5-point Likert scale (ranging from 1 = strongly disagree/very poor to 5 = strongly agree/excellent) by ten European rheumatology experts and with the help of appropriate statistical indicators calculated, the reliability of the LLMs was assessed. 2160 items were evaluated. All models demonstrated high performance in “Clinical Safety” (Means > 4.10). For “Clinical Accuracy”, DeepSeek and ChatGPT scored highest (Median 4.40 for both). Significant deviations were observed in “Completeness and Relevance”, where DeepSeek dominated (Mean 4.24, 95% CI 4.17–4.30) and Gemini showed the lowest performance (Mean 3.46, 95% CI 3.27–3.64). Inter-rater agreement was poor to slight (Fleiss’ kappa range: -0.043 to 0.059) and moderate for ICC (range: 0.259 to 0.692). LLMs currently exhibit uniformly strong safety behaviors when providing medical information about family planning, pregnancy and lactation in iRMD. However, significant differences exist regarding completeness and relevance, where DeepSeek and ChatGPT are currently the most reliable and complete models for this domain. Furthermore, the variability in responses and low inter-rater agreement highlight that LLMs require further parameterization, are useful tools for routine care, but cannot replace expert medical judgment.

16 November 2026 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
DVDiana Vossen
Diana Vossen
AKAnna Kernder
Anna Kernder
DODaniela Odehnal
Daniela Odehnal
DKDavid Kiefer
David Kiefer
IAIoana Andreica
Ioana Andreica
UKUta Kiltz
Uta Kiltz
Background: Women with inflammatory rheumatic and musculoskeletal disease (iRMD) face unique challenges during preconception, pregnancy, and lactation. In 2024, a specialised consultation service was developed and implemented at the tertiary rheumatology centre of the Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany, to address these specific needs. Methods: Demographic characteristics, disease- and treatment-related data, reproductive status, referring physician, reasons for consultation, and recommendations for disease management were collected between 1 January 2024 and 3 April 2025. Results: Overall, 57 patients were included; the mean age was 33.3 ± 4.4 years and the mean disease duration was 6.3 ± 4.8 years. Almost all patients (94.7%) had a confirmed diagnosis of an iRMD. 57.9% were planning a pregnancy, 40.4% were pregnant, and 1.8% were breastfeeding. At baseline, 21.8% were receiving csDMARDs and 50.9% were receiving bDMARDs. Glucocorticoid use was documented in 16.1%. Patients were referred by rheumatologists (35.7%), the in-house outpatient clinic (37.5%), general practitioners (14.3%), gynaecologists (10.7%), and the in-house inpatient clinic (1.8%). The most frequent reasons for consultation were patient concerns regarding pregnancy and medication safety. Consultation reasons differed descriptively between patients in the preconception period and pregnant patients; however, these exploratory differences should be interpreted with caution. Recommendations made during consultation included modification of DMARD therapy (35.1%), initiation of fetal bradycardia screening (19.3%), and preeclampsia prophylaxis (8.8%). Conclusion: A dedicated reproductive rheumatology consultation service provides structured support for women with iRMDs throughout preconception, pregnancy, and lactation. Medication adjustments and targeted preventive measures were recommended for more than one-third of patients, highlighting the potential value of preconception referral and specialized reproductive rheumatology consultation. Clinical trial number: Not applicable.